BioHealth Innovation, Inc. (BHI) has received the International Business Innovation Association (InBIA)’s January 2018 IMPACT Award in Biotech/Cleantech for the management of four spaces for early stage companies: the Germantown Innovation Center, the Rockville Innovation Center, LaunchLabs, and the BHI International Innovation Center.   The award is based on a variety of metrics including affiliations and partnerships, application and graduation, facilities, mission and goals.  This recognition also enables this innovation activity to be considered with other leading entrepreneurial centers across the country as a finalist for the InBIA’s annual Incubator of the Year Awards.  


Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil® (Anthrax Immune Globulin Intravenous [human]) to the Canadian government. This contract award follows the recent approval of Anthrasil by Health Canada under the Extraordinary Use New Drug (EUND) Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible. Anthrasil is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.


That Indians are not only heading global IT giants like Google and Microsoft but also a number of startups in diverse sectors, including biotechnology, across the US is evident from the fact that of the 52 companies operating out of the two innovation hubs in Rockville and Germantown in Maryland 11 are either headed or run by Indians.

From mobile technology platform connecting doctors and patients to pre-market cybersecurity for IoT (Internet of Things) devices, Indian Americans are the driving force behind several firms at the two innovation hubs managed by BioHealth Innovation, Inc, a non-profit public-private partnership, which aids early stage biotechnology companies from research to commercialization.


In 2010, an industry-led task force created in Montgomery County partnered with members of regional academia, government and other nonprofits to create an entrepreneurial innovation ecosystem that wasn’t being filled.

BioHealth Innovation Inc. (BHI), which was founded in 2012 by Richard Bendis in Rockville, Md., is designed to help bio-health companies grow, identify commercially relevant science, create new businesses and attract equity funding to the region. Bendis, who is also the president and CEO, has overseen the organization’s creation of unique programming for entrepreneurs at the National Institutes of Health, the University of Maryland and Johns Hopkins University.

Bendis AE1

Robust private-sector investment and prudent regulation from policymakers have helped establish Maryland as a cradle of innovation and a leader in the U.S. innovation economy. Few states can match Maryland's highly skilled workforce, market access and technology-centered policy incentives, and the U.S. Chamber of Commerce ranked Maryland No. 1 in the country for entrepreneurship and innovation.

But continued leadership of the region — and the ability of the region to continue to reap the economic and jobs benefits of innovation — is not a given. It requires constant cultivation and smart action from our elected officials.

Maryland is home to more than 800 life sciences companies, 70 federal labs and 16 colleges and universities, including National Institutes of Health, the Food and Drug Administration, Johns Hopkins University, the University System of Maryland and companies like MedImmune and GlaxoSmithKline. About 6 percent of Maryland's gross domestic product — $17.6 billion — is generated by the life sciences, and the biotechnology industry in Maryland alone employs about 34,000.

During the most recent legislative session in Maryland, the General Assembly considered a piece of onerous drug pricing legislation that threatened the biopharmaceutical ecosystem in the state while also potentially impeding access to care for Maryland patients.

In the name of "transparency," the legislation — which would have been the most hostile to industry in the country — imposed complex bureaucratic reporting requirements that disregarded the extraordinary development requirements and complex distribution channels for innovative drugs and therapies.

Read more via the Capital Gazette

BioHealth Innovation (BHI) is pleased to have the opportunity to discuss the entrepreneurial ecosystem in Maryland and the region.

BHI is a regional innovation intermediary which supports the transformation of research projects into new business opportunities in partnership with the region’s rich assets, institutions, and entrepreneurial community. BHI achieves this goal by being a catalytic partner in the economic development ecosystem which focuses on attracting, retaining, founding and reinventing biohealth businesses. BHI has built the infrastructure and track record to cofound and create new early stage biohealth startup and spinoff companies. In addition, BHI works directly with existing biohealth firms through a variety of supportive services including: incubation and accelerator programs, non-dilutive funding assistance, international soft landing programs and entrepreneur-in-residence support.



The Daily Record has named BioHealth Innovation Inc., (BHI) President and CEO Richard Bendis a 2017 Influential Marylander. Mr. Bendis is one of 51 Influential Marylanders who were selected by the publication for their significant contributions to their respective fields and leadership in the state.

“It’s an honor to be chosen as an Influential Marylander by The Daily Record. BHI has been working with our partners and other key stakeholders to help make Maryland a leader in the BioHealth Capital Region,” said Mr. Bendis. “Our success in supporting over 800 companies, scientists, and entrepreneurs since 2012 is a testament to the hard work and dedication of the entire BHI team.”

Mr. Bendis, along with the other Influential Marylanders, will be presented their awards on March 23, 2017 at a reception and dinner at The Grand Lodge of Maryland. The winners will also be profiled in a special magazine that will be inserted into the March 24th issue of The Daily Record and available online at

"Influential Marylanders help to shape their communities – our communities – for the better. They are at the pinnacle of their chosen professions and are role models for all of us," said Suzanne Fischer-Huettner, publisher of The Daily Record. "Their hard work, determination and commitment to excellence help us to realize our own hopes and dreams. The Daily Record is honored to recognize their accomplishments."

About BioHealth Innovation, Inc.

BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. BHI is known for providing commercial assistance to scientists and founders, educating and infusing Maryland's life science community with new and young entrepreneurs and fueling startups within Central Maryland's bio-ecosystem by connecting young companies to funding and business resources. Learn more at:

Click here to view all of the 2017 Influential Marylanders Honorees.


BioHealth Innovation inked a pair of recent deals to run incubators in Montgomery County.

The Rockville-based organization that works to help health and life sciences startups in the region is set to manage the Germantown Innovation Center and the Rockville Innovation Center. It’s the first foray into running incubators for the public-private partnership, which also helps startups coming out of UMB and Johns Hopkins in Baltimore.


Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple Tree Partners.

Concurrent with the financing, Corvidia has licensed a clinical stage compound from AstraZeneca to develop and commercialize as its lead therapeutic (COR-001).  Funds from the Series A financing will be used to progress COR-001 into Phase I/II clinical trials during 2016, as well as to advance the company's preclinical pipeline.

BHI Dept of Commerce Rotator

Today, U.S. Secretary of Commerce Penny Pritzker announced the 25 awardees that will receive $10 million under the Economic Development Administration’s (EDA) 2015 Regional Innovation Strategies (RIS) program. The 2015 RIS program is managed by EDA’s Office of Innovation and Entrepreneurship (OIE) and is designed to advance innovation and capacity-building activities in regions across the country through two different competitions: the i6 Challenge and the Seed Fund Support (SFS) Grants competition.

“As the driving force behind the Administration’s focus on entrepreneurship, the Department of Commerce is committed to helping set the conditions for innovators and entrepreneurs to test new ideas, take risks, find financing and customers, and ultimately thrive,” said Secretary Pritzker. “The Regional Innovation Strategies program is critical to ensuring that entrepreneurs have access to the tools they need to move their ideas and inventions from idea to market.”

Relevant Health

Hear from the exciting companies completing the first Relevant Health cohort! This event is currently invite only, but if you would like to find out more and possibly attend please send an email to This email address is being protected from spambots. You need JavaScript enabled to view it.

To find out more about the cohort, click here!

Md dept commerce bendis rotator

Sixteen leaders from key federal, academic and industry organizations have been appointed by Governor Larry Hogan to the Maryland Life Sciences Advisory Board (LSAB).

The new appointees include a patient advocate, executives from global life sciences companies with U.S. headquarters in Maryland, small biotechnology companies, and leaders from the University of Maryland, University of Maryland Baltimore, Johns Hopkin University, Montgomery College, NIH, FDA and the U.S. Army Medical Research and Material Command.